Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4C | Q9H3R0 | 4/20 | 0.48 |
| ▸ | KDM5A | P29375 | 2/20 | 0.48 |
| ▸ | KDM5B | Q9UGL1 | 2/20 | 0.48 |
| ▸ | MAPT | P10636 | 6/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | GPR142 | Q7Z601 | 3/20 | 0.45 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.43 |
| ▸ | XBP1 | P17861 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | GSK3A | P49840 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17610336 | 0.93 | CYP46A1 (0.44) | KDM4CKDM5AKDM5BMAPTRAB9A | |
| SCHEMBL17619630 | 0.90 | KDM4C (0.60) | KDM4CKDM5AKDM5BMAPTRAB9A | |
| SCHEMBL17619916 | 0.89 | MAPT (0.48) | KDM4CKDM5AKDM5BMAPTRAB9A | |
| SCHEMBL17619444 | 0.89 | KDM4C (0.46) | KDM4CKDM5AKDM5BMAPTNPSR1 | |
| SCHEMBL17610565 | 0.87 | GRM5 (0.53) | MAPTPOLBMAPK1 | |
| SCHEMBL17619523 | 0.86 | GRM5 (0.49) | MAPTPOLBMAPK1 | |
| SCHEMBL17619722 | 0.86 | KDM4C (0.44) | KDM4CKDM5AKDM5BMAPTPOLB | |
| SCHEMBL17619612 | 0.86 | KDM4C (0.41) | KDM4CKDM5AKDM5BMAPTMAPK1 | |
| SCHEMBL17619669 | 0.86 | KDM4C (0.54) | KDM4CKDM5AKDM5BMAPTENPP2 | |
| SCHEMBL17610459 | 0.84 | KDM4C (0.55) | KDM4CKDM5AKDM5BMAPTRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170291890-A1 | HETEROCYCLE SUBSTITUTED AMINO-PYRIDINE COMPOUNDS AND METHODS OF USE THEREOF | Epizyme, Inc. | 2017-10-12 | — | — | US | disclosed |
| WO-2016044666-A1 | HETEROCYCLE SUBSTITUTED AMINO-PYRIDINE COMPOUNDS AND METHODS OF USE THEREOF | Epizyme, Inc. (US) | 2016-03-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170291890-A1 | HETEROCYCLE SUBSTITUTED AMINO-PYRIDINE COMPOUNDS AND METHODS OF USE THEREOF | HCCS, TP53, NME2 | KDM4C 444/4885KDM5A 1394/4885KDM5B 1041/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.